Medications
Ticagrelor - Brilinta
BRILINTA is a P2Y12 platelet inhibitor indicated
• to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to
clopidogrel.
BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS.
• to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of BRILINTA was established in a population with
type 2 diabetes mellitus (T2DM).
• to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA).
Most common adverse reactions (>5%) are bleeding and dyspnea.
• Avoid use with strong CYP3A inhibitors or CYP3A inducers.
• Opioids: Decreased exposure to ticagrelor. Consider use of parenteral anti-platelet agent.
• Patients receiving more than 40 mg per day of simvastatin or lovastatin may be at increased risk of statin-related adverse effects.
• Monitor digoxin levels with initiation of or any change in BRILINTA.
• Avoid use with strong CYP3A inhibitors or CYP3A inducers.
• Opioids: Decreased exposure to ticagrelor. Consider use of parenteral anti-platelet agent.
• Patients receiving more than 40 mg per day of simvastatin or lovastatin may be at increased risk of statin-related adverse effects.
• Monitor digoxin levels with initiation of or any change in BRILINTA.
